Chinese drug maker Shenzhen Hepalink Pharmaceutical plans to invest US$60 million in TPG Biotechnology Partners V, L.P., which mainly targets biomedical technology and life science companies, the company announced in a statement (in Chinese).
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription?